Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 billion. BNT-327 is in the hot new class of bispecific antibodies targeting programmed death-1 (PD-1) or its ligand (PD-L1) and vascular endothelial growth factor (VEGF). The bispecifics take advantage of two well established mechanisms of action that help tumors grow; PD-1/PD-L1, which tells immunogenic T cells not to attack the tumor, and VEGF, which tumors excrete to produce new blood vessels to supply oxygen and other nutrients to the tumor.
Proteinqure Inc. has closed an $11 million series A financing round to support the initiation of the company’s first clinical trial for PQ-203, a first-in-class peptide-drug conjugate for triple-negative breast cancer (TNBC). The funds will also be used to advance additional pipeline programs in neurology and nephrology.
Cell division cycle 20 homolog (CDC20) is a key regulatory protein involved in mitotic progression. Aberrant overexpression of CDC20 has been implicated in tumorigenesis and is associated with poor prognosis in several cancers, including triple-negative breast cancer.
UTR Therapeutics Inc. has submitted an IND application to the FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC-driven cancers. Pending approval, a first-in-human phase I trial is slated to begin next year.
Triple-negative breast cancer is an especially challenging subtype characterized by the absence of key receptors, limiting the effectiveness of many standard breast cancer treatments.
Triple-negative breast cancer (TNBC), which accounts for up to 20% of cases of breast cancer, is one of the most aggressive and difficult to treat subtypes of the disease.
Breast cancer was the second most frequent cause of new cancer cases worldwide in 2024, and up to 20% of cases fall under the subtype of triple-negative breast cancer (TNBC), one of the most aggressive and difficult subtypes to treat.
Hangzhou Synrx Therapeutics Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of triple-negative breast cancer.
Korea University Research & Business Foundation Sejong Campus has described thiobenzimidazole derivatives reported to be useful for the treatment of breast cancer.
